Search results for "EPATOCARCINOMA"

showing 10 items of 33 documents

PREPARAZIONE E CARATTERIZZAZIONE DI NANOSISTEMI LIPIDICI PER IL DIREZIONAMENTO E IL RILASCIO MODIFICATO DI FARMACI E ACIDI NUCLEICI IN TERAPIA ONCOLO…

2016

sono stati sviluppati sistemi nanoparticellari in grado di intrappolare elevate quantità di farmaci e di legare materiale genico. I sistemi preparati sono stati caratterizzati da un punto di vista chimico-fisico e tecnologico farmaceutico. Sono stati infine utilizzati per prove in vitro e i risultati ottenuti hanno mostrato che essi possiedono le caratteristiche per potere essere considerati dei validi carrier per farmaci e materiale genico nel trattamento oncologico.

nanoparticelleterapia genicatumorecarcinoma ovariconanoparticelle; cancro; terapia genica; antitumorali; drug delivery; epatocarcinoma; carcinoma ovaricocaratterizzazioneSettore CHIM/09 - Farmaceutico Tecnologico Applicativodrug and gene deliverydrug deliverycancroantitumoraliepatocarcinoma
researchProduct

The synthetic cannabinoid WIN sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis by activating p8/CHOP/DR5 axis.

2010

In this paper we demonstrate that the synthetic cannabinoid WIN sensitizes human hepatocellular carcinoma (HCC) cells to apoptosis mediated by TNF-related apoptosis inducing ligand (TRAIL). The apoptotic mechanism induced by treatment with WIN/TRAIL combination involved the loss of the mitochondrial transmembrane potential and led to the activation of caspases. In HCC cells WIN treatment induced up-regulation of TRAIL death receptor DR5, an effect which seemed to be related to the increase in the level of p8 and CHOP, two factors implicated in cellular stress response and apoptosis. This relationship was suggested by the observation that the down-regulation of p8 or CHOP by specific siRNAs …

Settore BIO/10 - Biochimicacannabinoids TRAIL ER-stress hepatocarcinoma
researchProduct

POLIMORFISMI A SINGOLO NUCLEOTIDE ( SINGLE NUCLEOTIDE POLYMORPHISMS, SNPs) COME POSSIBILI MARCATORI GENETICI PER LA VALUTAZIONE DEL RISCHIO DI SVILUP…

Settore MED/09 - Medicina InternaCIRROSIPOLIMORFISMIEPATOCARCINOMAPOLIMORFISMI; CIRROSI; EPATOCARCINOMA;
researchProduct

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy

2021

Valentina Burgio,1 Massimo Iavarone,2 Giovanni Giuseppe Di Costanzo,3 Fabio Marra,4 Sara Lonardi,5,6 Emiliano Tamburini,7 Fabio Piscaglia,8 Gianluca Masi,9,10 Ciro Celsa,11 Francesco Giuseppe Foschi,12 Marianna Silletta,13 Daniela Caterina Amoruso,14 Margherita Rimini,15 Mariangela Bruccoleri,2 Raffaella Tortora,3 Claudia Campani,4 Caterina Soldà,6 Massimo Giuseppe Viola,16 Antonella Forgione,8 Fabio Conti,12 Francesca Salani,9,10 Silvia Catanese,9,10 Carmelo Marco Giacchetto,17 Claudia Fulgenzi,13 Carmine Coppola,14 Pietro Lampertico,18 Antonio Pellino,6,19 Gabriele Rancatore,17 Giuseppe Cabibbo,17 Francesca Ratti,20 Federica Pedica,21 Angelo Della Corte,22 Massimo Colombo,18 Francesco De…

Oncologysorafenib.Cancer Management and ResearchhepatocarcinomaNeoplasms. Tumors. Oncology. Including cancer and carcinogenssorafeniblenvatinibneoplasmsdigestive system diseasesRC254-282Original ResearchCancer Management and Research
researchProduct

Delivery of shRNA plasmid DNA by cationic solid lipid nanoparticles for gene silencing in human hepatocarcinoma cells

2015

hepatocarcinoma cationic nanoparticles
researchProduct

ESPRESSIONE DI VEGF, HSP90 E Bip/GRP78 E RICORRENZA DI CARCINOMA EPATOCELLULARE DOPO TRAPIANTO DI FEGATO

Background and aims Liver transplantation (LT) for hepatocellular carcinoma (HCC) is a satisfactory therapeutic choice in patients with “early HCC” selected according to Milan criteria. However, the risk of HCC recurrence after LT is about 7-10% at five years and markers which can predict recurrence are still lacking. We investigated in HCC samples and LC surrounding tissues the significance of VEGF, HSP90, and Bip/GRP78 expression in patients with HCC who underwent LT in a western transplantation center and their possible role as markers of recurrence. Background and aims Liver transplantation (LT) for hepatocellular carcinoma (HCC) is a satisfactory therapeutic choice in patients with “ea…

EPATOCARCINOMA E VEGF HSP90 Bip/grp78Settore MED/09 - Medicina Interna
researchProduct

Ruolo dei pattern ecografici nella sorveglianza per la diagnosi precoce dell'HCC

EcografiacirrosiEcografia; epatocarcinoma; sorveglianza; cirrosisorveglianzaepatocarcinoma
researchProduct

EPATOMI MALIGNI DEL BAMBINO

1991

I tumori magli del fegato in età pediatrica sono rappresentati da due forme istologiche differenti: l'Epatoblastoma (EPB) e l'Epatocarcinoma (EPC). Gli Autori esaminano le caratteristiche cliniche, la stadiazione e gli aspetti terapeutici. Vengono altresì presentati i dati della letteratura ed i risultati del Protocollo Italiano di cura di queste neoplasie.

Settore MED/38 - Pediatria Generale E SpecialisticaSettore MED/20 - Chirurgia Pediatrica E InfantileTumori del bambino tumori del fegato epatoblastoma epatocarcinoma
researchProduct

Pekinenin E Inhibits the Growth of Hepatocellular Carcinoma by Promoting Endoplasmic Reticulum Stress Mediated Cell Death.

2017

Hepatocellular carcinoma (HCC) is a malignant primary liver cancer with poor prognosis. In the present study, we report that pekinenin E (PE), a casbane diterpenoid derived from the roots of Euphorbia pekinensis, has a strong antitumor activity against human HCC cells both in vitro and in vivo. PE suppressed the growth of human HCC cells Hep G2 and SMMC-7721. In addition, PE-mediated endoplasmic reticulum (ER) stress caused increasing expressions of C/EBP homologous protein (CHOP), leading to apoptosis in HCC cells both in vitro and in vivo. Inhibition of ER stress with CHOP small interfering RNA or 4-phenyl-butyric acid partially reversed PE-induced cell death. Furthermore, PE induced S ce…

0301 basic medicineProgrammed cell deathSmall interfering RNAPathologymedicine.medical_specialtyCell cycle checkpointCHOP03 medical and health sciencesmedicinePharmacology (medical)Original ResearchPharmacologybusiness.industryEndoplasmic reticulumlcsh:RM1-950apoptosisdigestive system diseasesHep G2030104 developmental biologylcsh:Therapeutics. PharmacologyApoptosishepatocarcinomacell cycle arrestUnfolded protein responseCancer researchbusinessER stresspekinenin EFrontiers in pharmacology
researchProduct

Nanoparticelle per il rilascio controllato di Sorafenib

2017

Sorafenib nanoparticelle poliaspartammide epatocarcinomaSettore CHIM/09 - Farmaceutico Tecnologico Applicativo
researchProduct